Immorta Bio's combined senolytic immunotherapy and regenerative cellular platform produced over 70% lifespan extension in aged animal models, alongside improvements in organ function, tissue repair, and markers of cellular recovery. The finding demonstrates that simultaneous clearance of senescent cells and activation of regenerative capacity can produce measurable gains in both lifespan and healthspan across multiple physiological domains.
Key Points
- 70% lifespan extension achieved in validated aging models
- Dual approach: senescent cell clearance plus regenerative signaling activation
- Improvements in liver function, tissue repair, recovery biomarkers
Longevity Analysis
This work addresses a fundamental principle in aging biology: senescent cells accumulate with age and impair tissue regeneration, while simultaneously suppressing the body's capacity to repair and restore function. By removing these dysfunctional cells while reactivating cellular regeneration pathways, the intervention targets both a primary driver of deterioration and the loss of tissue capacity that characterizes aging. The magnitude of effect—70% lifespan extension—reflects improvement across multiple physiological domains rather than a single pathway, suggesting that coordinated intervention at the intersection of cellular senescence and regenerative signaling may unlock greater gains than single-target approaches. These results in animal models warrant close monitoring as the therapy advances toward clinical development, particularly regarding translability to human aging trajectories and which populations might benefit most.
Original published by Longevity.Technology.